PROTEIN
POLYMER TECHNOLOGIES ANNOUNCES ELECTION OF BOARD OF DIRECTORS
SAN DIEGO, May 27 -- Protein Polymer
Technologies, Inc. (OTC Bulletin Board: PPTI) announces
the election of the Company's Board of Directors at its
Annual Meeting
of Shareholders. Elected to initial terms were William
N. Plamondon III, Chief Executive
Officer of Protein Polymer Technologies, Inc., and James
B. McCarthy,
Chairman and CEO of the Gemini Consulting Group, Inc. Reelected
to the
Company's Board of Directors were: Donald Kaplan, Ph.D.,
President and
Chief Operating Officer, Protein Polymer Technologies,
Inc.,
Edward G. Cape, Ph.D.
Kerry L. Kuhn, M.D., Steven M. Lamon, Steve Peltzman, and
J. Thomas Parmeter,
Ph.D., Chairman, Protein Polymer Technologies, Inc. All
Directors are elected
to annual terms.
Donald Kaplan, Ph.D. presented the company technical report which included the
status of the company's dermal product clinical testing. He also updated
the
status of negotiations with potential marketing partners for the tissue sealant
product, and reviewed the current standing of the company's IDN product which
has been licensed to Spine Wave.
In other business, stockholders also ratified Peterson & Company, LLP, as
the
Company's independent public accountants for the 2004 fiscal year.
Contacts
J. Thomas Parmeter, Ph.D.
Chairman
Protein Polymer Technologies, Inc.
(858) 558-6064
info@ppti.com |
Erin Davis
Director of Communications and Investor Relations
Protein Polymer Technologies, Inc.
(858) 558-6064 x 120
edavis@ppti.com
|
About
Protein Polmer Technologies
Protein Polymer Technologies,
Inc., is a San Diego-based company focused on developing
bioactive devices to improve
medical and surgical outcomes. From its inception in
1988, PPTI has been a pioneer in protein design and
synthesis, creating an extensive portfolio of proprietary
biomaterials
for use in the development of bioactive devices. These
genetically engineered biomaterials are high molecular
weight proteins, processed into products with physical
and biological characteristics tailored to specific
clinical performance requirements. Targeted products
include urethral
bulking agents for the treatment of stress urinary
incontinence, dermal augmentation products for cosmetic
and reconstructive
surgery, surgical adhesives and sealants, scaffolds
for wound healing and tissue engineering, and depots
for
local drug delivery. To date, PPTI has been issued
twenty-six U.S. Patents on its core technology with
corresponding
issued and pending patents in key international markets.
Safe Harbor
This press release contains forward-looking statements
that are based on management’s views and expectations.
Actual results could differ materially from those expressed
here; further, the Company is not obligated to comment
specifically on those differences. Risks associated with
the Company’s activities include raising adequate
capital to continue operations scientific and product
development uncertainties, competitive products and approaches,
continuing collaborative partnership interest and funding,
regulatory testing and approvals, and manufacturing scale
up. The reader is encouraged to refer to the Company’s
2004
Annual Report Form 10-KSB, and other recent filings
with the Securities and Exchange Commission, copies of
which are available from the Company, to further ascertain
the risks associated with the above statements.
